Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 66.32% | -366.89% | 1.39% | -55.55% | 36.18% |
| Total Depreciation and Amortization | -40.00% | -9.09% | -8.33% | -47.83% | -30.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.29% | 1,181.12% | 164.16% | -0.88% | 4.00% |
| Change in Net Operating Assets | -218.59% | 326.94% | -171.04% | 158.23% | -199.91% |
| Cash from Operations | -43.47% | -27.45% | 1.48% | -12.66% | 3.90% |
| Capital Expenditure | -- | -- | -- | 100.00% | 75.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 133.86% | -333.16% | 135.66% | -30.18% | -2,256.08% |
| Cash from Investing | 133.86% | -333.16% | 135.66% | -30.16% | -2,209.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.86% | 15,877.02% | -45.41% | 1,639.39% | -98.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.52% | -113.03% | -- | -- | -- |
| Cash from Financing | 207.77% | 93.96% | 4,116.96% | 1,639.39% | -94.66% |
| Foreign Exchange rate Adjustments | -2,927.27% | -56.00% | 110.59% | -353.85% | -136.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8,011.92% | -106.88% | 146.91% | -23.74% | -205.94% |